Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms

• Published in: Oncotarget Vol. 9; no. 80; pp. 35181 - 35194
• Main Authors: Griesinger, Frank, Roeper, Julia, Pöttgen, Christoph, Willborn, Kay C., Eberhardt, Wilfried E.E.
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 12.10.2018
• Subjects: Review; non-small cell lung cancer; ALK-positive; ALK-inhibitors; brain metastases
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.26073

The progress in molecular biology has revolutionized systemic treatment of advanced non-small-cell lung cancer (NSCLC) from conventional chemotherapy to a treatment stratified by histology and genetic aberrations. Tumors harboring a translocation of the anaplastic-lymphoma-kinase (ALK) gene constitute a distinct genetic and clinico-pathologic NSCLC subtype with patients with ALK-positive disease being at a higher risk for developing brain metastases. Due to the introduction of effective targeted therapy with ALK-inhibitors, today, patients with advanced ALK-positive NSCLC achieve high overall response rates and remain progression-free for long time intervals. Moreover, ALK-inhibitors seem to exhibit efficacy in the treatment of brain metastases. In the light of this, it needs to be discussed how treatment algorithms for managing patients with brain metastases should be modified. By integrating systemic ALK-inhibitor therapy, radiotherapy, in particular whole brain radiotherapy might be postponed deferring potential long-term impairment by neurocognitive deficits to a later time point in the course of the disease. An early treatment of asymptomatic brain metastases might offer patients a longer time without impairment of cerebral symptoms or radiotherapeutic interventions. Based on an updated extensive review of the literature this article provides an overview on the epidemiology and the treatment of patients' brain metastases. It describes the specifics of ALK-positive disease and proposes an algorithm for the treatment of patients with advanced ALK-positive NSCLC and brain metastases.